1
|
Liang Z, He Z, Chen C, Zhang F, Li J, Wu J. Microscopic testicular sperm extraction or post-operative sperm reversal in functional Leydig cell tumor: case report. Transl Androl Urol 2019; 8:556-561. [PMID: 31807432 DOI: 10.21037/tau.2019.08.10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Leydig cell tumors are rare testicular tumors in adults. Hormonal activity is found in 20% of the cases with endocrine abnormalities, which may result in azoospermia. The appropriate management to achieve oncologic control and simultaneously obtain sperm remains a challenge. A patient sought assistance with fertility after a diagnosis of azoospermia accompanied by unilateral suspected Leydig cell tumor. The patient underwent unilateral orchidectomy along with microscopic testicular sperm extraction (mTESE) for sperm identification. Rare teratospermia was found during mTESE, hormones tended to be normal, and sperm reversal appeared postoperatively. Postoperative semen examination revealed oligozoospermia, and the parameters decreased further after 3 months. The androgen rebound effect promoted sperm level over the baseline within 3 months after surgery. The anticipated sperm reversal postoperatively rather than mTESE during routine orchidectomy achieved sperm acquisition. This case particularly highlights the androgen rebound effect, which elevated the sperm level beyond baseline within 3 months after surgery. Sperm cryopreservation is thus strongly recommended 3 months postoperatively and no more than 4 months.
Collapse
Affiliation(s)
- Zhongyan Liang
- Reproductive Medicine Center, Department of Urology and Andrology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
| | - Zhanwang He
- Department of Reproductive Medicine Center, Ninghai Maternal and Child health Hospital, Ninghai 315600, China
| | - Chong Chen
- Department of Ultrasonography, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
| | - Fengbin Zhang
- Reproductive Medicine Center, Department of Urology and Andrology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
| | - Jingping Li
- Reproductive Medicine Center, Department of Urology and Andrology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
| | - Jinggen Wu
- Reproductive Medicine Center, Department of Urology and Andrology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China
| |
Collapse
|
2
|
Muheilan MM, Shomaf M, Tarawneh E, Murshidi MM, Al-Sayyed MR, Murshidi MM. Leydig cell tumor in grey zone: A case report. Int J Surg Case Rep 2017; 35:12-16. [PMID: 28419904 PMCID: PMC5394201 DOI: 10.1016/j.ijscr.2017.03.043] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2017] [Revised: 03/31/2017] [Accepted: 03/31/2017] [Indexed: 11/12/2022] Open
Abstract
Leydig cell tumor is a testicular tumor with a low incidence accounting for 1–3% of testicular neoplasms. Only about 10% of them show malignant behavior in the form of metastatic disease. When diagnosed and treated early, long-term favorable outcomes are seen even with its potential metastatic behavior.
Introduction Leydig cell tumor constitutes only about 1–3% of testicular neoplasms. There is apparently increased incidence in the last few years; one possible explanation for this phenomenon is the widespread use of ultrasound technology and the subsequent increased early detection of smaller lesions that have not been found in historical series. Case presentation We report a case of Leydig cell tumor of testis in a patient presenting with painless long standing slowly growing left scrotal mass who found to have intrapulmonary nodule and multiple enlarged retroperitoneal lymph nodes on staging work up. The mass was managed by radical orchiectomy. Pathological diagnosis was Leydig cell tumor. Discussion Orchiectomy is the accepted mode of treatment but follow-up every 3–6 months with physical examination, hormone assays, scrotal and abdominal ultrasonography, chest radiography, and CT scans is essential in such a case with a potential for malignant behavior. Conclusion Inguinal orchiectomy is the therapeutic decision of choice and long-term follow-up is necessary to exclude recurrence or metastasis. Cases which fall in the grey zone like ours need to be followed up carefully for metastasis instead of rushing into an early retroperitoneal lymph node dissection, with its potential risks and complications.
Collapse
Affiliation(s)
- Muheilan Mustafa Muheilan
- Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Jordan.
| | - Maha Shomaf
- Department of Pathology and Microbiology and Forensic Medicine, Jordan University Hospital, The University of Jordan, Jordan.
| | - Emad Tarawneh
- Department of Radiology, Jordan University Hospital, The University of Jordan, Jordan.
| | | | - Manar Rizik Al-Sayyed
- Department of Pathology and Microbiology and Forensic Medicine, Jordan University Hospital, The University of Jordan, Jordan.
| | - Mujalli Mhailan Murshidi
- Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Jordan.
| |
Collapse
|
3
|
Corlan AS, Cîmpean AM, Jitariu AA, Melnic E, Raica M. Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Cancer Development and Tumor Angiogenesis. Int J Endocrinol 2017; 2017:3232905. [PMID: 28386275 PMCID: PMC5366234 DOI: 10.1155/2017/3232905] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/07/2016] [Revised: 01/15/2017] [Accepted: 01/23/2017] [Indexed: 12/26/2022] Open
Abstract
A lot of data suggests endocrine gland-derived vascular endothelial growth factor (EG-VEGF) to be restricted to endocrine glands and to some endocrine-dependent organs. Many evidences show that EG-VEGF stimulates angiogenesis and cell proliferation, although it is not a member of the VEGF family. At the time, a lot of data regarding the role of this growth factor in normal development are available. However, controversial results have been published in the case of pathological conditions and particularly in malignant tumors. Thus, our present paper has been focused on the role of EG-VEGF in normal tissues and various malignant tumors and their angiogenic processes.
Collapse
Affiliation(s)
- Ana Silvia Corlan
- Department of Endocrinology, “Vasile Goldis” University of Arad, Arad, Romania
| | - Anca Maria Cîmpean
- Department of Microscopic Morphology/Histology, Angiogenesis Research Center, “Victor Babeș” University of Medicine and Pharmacy Timișoara, Timișoara, Romania
- *Anca Maria Cîmpean:
| | - Adriana-Andreea Jitariu
- Department of Microscopic Morphology/Histology, Angiogenesis Research Center, “Victor Babeș” University of Medicine and Pharmacy Timișoara, Timișoara, Romania
| | - Eugen Melnic
- Department of Pathology, “Nicolae Testemitanu” University of Medicine and Pharmacy, Chișinău, Moldova
| | - Marius Raica
- Department of Microscopic Morphology/Histology, Angiogenesis Research Center, “Victor Babeș” University of Medicine and Pharmacy Timișoara, Timișoara, Romania
| |
Collapse
|
4
|
Gheorghisan-Galateanu AA. Leydig cell tumors of the testis: a case report. BMC Res Notes 2014; 7:656. [PMID: 25230718 PMCID: PMC4175283 DOI: 10.1186/1756-0500-7-656] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2014] [Accepted: 09/16/2014] [Indexed: 02/11/2023] Open
Abstract
BACKGROUND Leydig cell tumors are the most common non-germ cell gonadal tumors with apparent increased incidence in the last few years. They are usually benign tumors. We report a case of Leydig cell tumor of testis in a patient presenting atypical features. CASE PRESENTATION A 29-year-old Caucasian man, born with right cryptorchidism, corrected without medical treatment before the age of two years, was diagnosed with Leydig cell tumor. Two years after diagnosis was identified moderately elevated estradiol serum level, in the context of a significant overweight, hormonal changes which had maintained after unilateral orchiectomy and after the patient's return to normal weight. Four years after unilateral orchiectomy, elevated value of estradiol persisted and subdiaphragmatic micro lymphadenopathy was observed. CONCLUSIONS Despite the favorable evolution of the patient four years after unilateral orchiectomy, long-term follow-up is necessary to exclude recurrence or metastasis to the testis. The endocrine profile and imaging investigations need to be repeated periodically. The changes in the hormonal assay and any new aspects on computed tomography scan can be used as a marker of tumor recurrence and require careful screening and the correct therapeutic decisions.
Collapse
|
5
|
Cailleux-Bounacer A, Rohmer V, Lahlou N, Lefebvre H, Roger M, Kuhn JM. Impact level of dihydrotestosterone on the hypothalamic-pituitary-leydig cell axis in men. ACTA ACUST UNITED AC 2007; 32:57-65. [PMID: 17931384 DOI: 10.1111/j.1365-2605.2007.00818.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Dihydrotestosterone (DHT) the physiologically most potent androgen cannot be aromatised into oestrogen. DHT is used as a treatment for idiopathic gynaecomastia. In order to investigate the different sites of action of DHT on the hypothalamic-pituitary-testicular axis, two groups of adult men were studied. Group I included 10 gonadotropin-releasing hormone (GnRH)-deficient men who were evaluated before and during a pulsatile infusion of GnRH alone for 2 weeks and then in association with DHT given transdermally at doses used in the treatment of gynaecomastia for further two weeks. Luteinizing hormone (LH) pulsatility was assessed at the end of each step of the study. Plasma LH levels were measured every 15 min. Plasma testosterone (T), DHT, oestradiol (E2), free alpha-subunit (FAS) of glycoproteic hormones and LH bioactivity were measured on pooled plasma samples. Group II included 12 healthy men in whom plasma T, DHT and E2 were measured before and then 24, 48 and 72 h after the injection of 5000 IU hCG alone or in combination with either DHT or the pure anti-androgen nilutamide. Two weeks separated each of the 3 hCG testing. In group I, except for bioactive/immunoreactive (B/I) LH ratio which was unchanged, GnRH treatment induced significant rises (p < 0.01) in all plasma hormone levels, LH pulse amplitude and frequency. During treatment with GnRH+DHT, plasma DHT levels increased up to 16.8 +/- 2.5 nm, while plasma hormone levels, B/I LH ratio, LH pulse amplitude and frequency were similar to those obtained with GnRH alone. In group II, the peak of hCG-induced T rise was not modified by either DHT or nilutamide. In contrast, DHT reduced by 50% (p < 0.01) the E2 peak in response to hCG. These data show that DHT exerts no direct action on the pituitary to retroregulate LH secretion and to modify either B/I LH ratio or FAS secretion. Its reducing effect on LH secretion is likely mediated at the hypothalamic level. DHT does not appear to have a physiological influence on Leydig cells steroidogenesis. Administered at therapeutic doses, DHT directly reduces testicular aromatase activity that combined with its antigonadotropic effect leads to the gain in the symptomatic treatment of gynaecomastia.
Collapse
Affiliation(s)
- Anne Cailleux-Bounacer
- Department of Endocrinology and Clinical Investigation Center INSERM 0204, University of Rouen, Bois Guillaume, France
| | | | | | | | | | | |
Collapse
|
6
|
Huyghe E, Nohra J, Vezzozi D, Daudin M, Bennet A, Caron P, Thonneau P, Plante P. [Fertility before and after treatment of patients with Leydig cell tumour]. Prog Urol 2007; 17:841-5. [PMID: 17633998 DOI: 10.1016/s1166-7087(07)92304-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE To determine the long-term fertility status of patients treated for Leydig cell testicular tumour. MATERIAL AND METHODS [corrected] In a series of 506 testicular tumours observed in the Midi-Pyrenées region between 1980 and 1998, 17 were Leydig cell tumours (3.3%) and constituted the study population. Andrological records were available for all patients. Information concerning fertility before and after orchidectomy was obtained by validated letter questionnaire. All patients completed the questionnaire. RESULTS The mean follow-up was 84 months (range: 36-173). The mean age at diagnosis was 32 years (range: 24-51). The presenting symptom was gynaecomastia in 9 cases (53%), enlarged testis in 4 cases (24%), scrotal pain in 2 cases (12%) and male infertility in 2 cases (12%). Before onset of their disease, 13/17 (76.5%) patients had tried to have a child and 6 (46.2%) had successfully fathered a child. After treatment of their Leydig cell tumour, 10/17 (58.8%) had tried to have a child and 7 (70%) were successful. CONCLUSION The population of men with Leydig cell tumour of the testis is a population with decreased fertility before treatment of the tumour. Resection of the tumour improves this situation, but 3 out of 10 patients remain infertile, indicating the need for semen storage measures in this population.
Collapse
Affiliation(s)
- Eric Huyghe
- Service d'Urologie et Andrologie, Hôpital Paule de Viguier Toulouse, France.
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Douglas ML, Richardson MM, Nicol DL. Testicular germ cell tumors exhibit evidence of hormone dependence. Int J Cancer 2005; 118:98-102. [PMID: 16032706 DOI: 10.1002/ijc.21330] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The aim of this investigation was to test the hypothesis that testicular germ cell tumors (TGCTs) are hormone-dependent cancers. Human TGCT cells were implanted in the left testis of male severe combined immunodeficient mice receiving either no treatment or hormone manipulation treatment [blockade of gonadotropin-releasing hormone secretion and/or signaling using leuprolide or leuprolide plus exogenous testosterone]. Real-time RT-PCR analysis was used to determine the expression profiles of hormone pathway-associated genes. Tumor burden was significantly smaller in mice receiving both leuprolide and testosterone. Real-time RT-PCR analysis of follicle-stimulating hormone (FSH) receptor, luteinizing hormone (LH) receptor and P450 aromatase revealed changes in expression in normal testis tissue related to presence of xenograft tumors and manipulation of hormone levels but a complete absence of expression of these genes in tumor cells themselves. This was confirmed in human specimens of TGCT. Reduced TGCT growth in vivo was associated with significant downregulation of LH receptor and P450 aromatase expression in normal testes. In conclusion, manipulation of hormone levels influenced the growth of TGCT in vivo, while the presence of xenografted tumors influenced the expression of hormone-related genes in otherwise untreated animals. Human TGCTs, both in the animal model and in clinical specimens, appear not to express receptors for FSH or LH. Similarly, expression of the P450 aromatase gene is absent in TGCTs. Impaired estrogen synthesis and/or signaling may be at least partly responsible for inhibition of TGCT growth in the animal model.
Collapse
Affiliation(s)
- Meaghan L Douglas
- School of Medicine, Southern Clinical Division, University of Queensland, Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia
| | | | | |
Collapse
|
8
|
Samson M, Peale FV, Frantz G, Rioux-Leclercq N, Rajpert-De Meyts E, Ferrara N. Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. J Clin Endocrinol Metab 2004; 89:4078-88. [PMID: 15292351 DOI: 10.1210/jc.2003-032024] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
Angiogenesis is essential for tumor growth and metastasis. A new human angiogenic mitogen, endocrine gland-derived vascular endothelial growth factor (EG-VEGF), has been recently identified; its expression pattern is restricted to endocrine glands, with the highest expression in testis. We used in situ hybridization and newly generated monoclonal antibodies to investigate the expression of EG-VEGF in normal human prenatal and adult testis and in 48 human testicular tumors of different subtypes. We found that EG-VEGF was expressed from 14 wk until birth in human fetal testis. In the adult testis, EG-VEGF was strongly expressed only in Leydig cells. In testicular tumors, EG-VEGF was expressed specifically in Leydig cell tumors, whereas germ cell-derived neoplasms, including carcinoma in situ, seminoma, and nonseminomatous germ cell tumors, were negative for this antigen. In contrast, VEGF, another powerful angiogenic factor, was expressed in seminoma, but very weakly in Leydig cell tumors. Interestingly, we found that Leydig cell tumors presented vessel surface density 3.2-fold higher than seminoma. These findings argue that human EG-VEGF may play a role in angiogenesis both during the early endocrine development of testis and in the adult testis as well as in Leydig cell tumor growth.
Collapse
Affiliation(s)
- Michel Samson
- Department of Molecular Oncology, Genentech, Inc., South San Francisco, California 94080, USA
| | | | | | | | | | | |
Collapse
|
9
|
|